Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Siwen Hu

Showing results (61-70 of 100) with videos related to

Pageof 10
Sort By:
Cancer Immunology Research|September 4, 2016
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T CellsBlanca Homet Moreno, Jesse M Zaretsky, Angel Garcia-Diaz, et al.
Cell Reports. Medicine|December 9, 2020
Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1Asaf Poran, Julian Scherer, Meghan E Bushway, et al.
Cancer Reports (Hoboken, N.J.)|January 8, 2024
Comparing the rate of immunotherapy treatment change due to toxicity by sexKevin J Chua, Shane Kronstedt, Alain Kaldany, et al.
Frontiers in Immunology|September 6, 2023
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcomeJohn Marsiglio, Jordan P McPherson, Magdalena Kovacsovics-Bankowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2017
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid TumorsAnthony W Tolcher, Mario Sznol, Siwen Hu-Lieskovan, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 4, 2025
Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate CancersJordan Fenlon, Nathan Van Bibber, Jonathon Mahlow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2011
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patientsSiwen Hu-Lieskovan, Daniel Vallbohmer, Wu Zhang, et al.
Journal for Immunotherapy of Cancer|December 3, 2020
SITC cancer immunotherapy resource document: a compass in the land of biomarker discoverySiwen Hu-Lieskovan, Srabani Bhaumik, Kavita Dhodapkar, et al.
Cell|March 22, 2016
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaWilly Hugo, Jesse M Zaretsky, Lu Sun, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2018
Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC moleculesMichael T Bethune, Xiao-Hua Li, Jiaji Yu, et al.
Pageof 10

Showing results (61-70 of 100) with videos related to

Sort By:
Pageof 10
Cancer Immunology Research|September 4, 2016
Response to Programmed Cell Death-1 Blockade in a Murine Melanoma Syngeneic Model Requires Costimulation, CD4, and CD8 T CellsBlanca Homet Moreno, Jesse M Zaretsky, Angel Garcia-Diaz, et al.
Cell Reports. Medicine|December 9, 2020
Combined TCR Repertoire Profiles and Blood Cell Phenotypes Predict Melanoma Patient Response to Personalized Neoantigen Therapy plus Anti-PD-1Asaf Poran, Julian Scherer, Meghan E Bushway, et al.
Cancer Reports (Hoboken, N.J.)|January 8, 2024
Comparing the rate of immunotherapy treatment change due to toxicity by sexKevin J Chua, Shane Kronstedt, Alain Kaldany, et al.
Frontiers in Immunology|September 6, 2023
A single center case series of immune checkpoint inhibitor-induced type 1 diabetes mellitus, patterns of disease onset and long-term clinical outcomeJohn Marsiglio, Jordan P McPherson, Magdalena Kovacsovics-Bankowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 22, 2017
Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid TumorsAnthony W Tolcher, Mario Sznol, Siwen Hu-Lieskovan, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 4, 2025
Human Immunodeficiency Virus-Associated Differences in the Tumor Immune Microenvironment of Lung, Breast, and Prostate CancersJordan Fenlon, Nathan Van Bibber, Jonathon Mahlow, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2011
EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patientsSiwen Hu-Lieskovan, Daniel Vallbohmer, Wu Zhang, et al.
Journal for Immunotherapy of Cancer|December 3, 2020
SITC cancer immunotherapy resource document: a compass in the land of biomarker discoverySiwen Hu-Lieskovan, Srabani Bhaumik, Kavita Dhodapkar, et al.
Cell|March 22, 2016
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic MelanomaWilly Hugo, Jesse M Zaretsky, Lu Sun, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 24, 2018
Isolation and characterization of NY-ESO-1-specific T cell receptors restricted on various MHC moleculesMichael T Bethune, Xiao-Hua Li, Jiaji Yu, et al.
Pageof 10